Cite
Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells.
MLA
Motte, Jeremias, et al. “Treatment of Concomitant Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome with Autologous CD19-Targeted CAR T Cells.” Neuron, vol. 112, no. 11, June 2024, p. 1757. EBSCOhost, https://doi.org/10.1016/j.neuron.2024.04.014.
APA
Motte, J., Sgodzai, M., Schneider-Gold, C., Steckel, N., Mika, T., Hegelmaier, T., Borie, D., Haghikia, A., Mougiakakos, D., Schroers, R., & Gold, R. (2024). Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. Neuron, 112(11), 1757. https://doi.org/10.1016/j.neuron.2024.04.014
Chicago
Motte, Jeremias, Melissa Sgodzai, Christiane Schneider-Gold, Nina Steckel, Thomas Mika, Tobias Hegelmaier, Dominic Borie, et al. 2024. “Treatment of Concomitant Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome with Autologous CD19-Targeted CAR T Cells.” Neuron 112 (11): 1757. doi:10.1016/j.neuron.2024.04.014.